Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
Vaxcyte (Nasdaq: PCVX) said management will take part in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT. A live webcast will be available on the company investor site, with a replay for ~30 days.
Positive
- None.
Negative
- None.
News Market Reaction – PCVX
In the Apr 8 session, PCVX declined 0.97%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 23 | Phase 3 enrollment | Positive | +2.2% | Completed enrollment of OPUS-1 and OPUS-2 Phase 3 VAX-31 adult trials. |
| Mar 18 | Clinical data update | Positive | -0.6% | Published positive VAX-31 Phase 1/2 adult data in The Lancet Infectious Diseases. |
| Feb 24 | Earnings and financing | Positive | +2.8% | Reported FY 2025 results, strong cash of ~$2.44B and $632.5M public offering. |
| Feb 11 | Phase 3 trial start | Positive | -0.7% | Dosed first participants in OPUS-3 Phase 3 trial for VAX-31 in adults. |
| Feb 10 | Earnings date notice | Positive | +0.7% | Announced timing of Q4 and full-year 2025 results and business update call. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often generated mixed reactions, with positive clinical and financial updates sometimes met by both gains and modest pullbacks.
Over the past few months, Vaxcyte reported several key milestones. Positive VAX-31 Phase 1/2 data and initiation and completion of enrollment across OPUS Phase 3 adult trials signaled clinical and regulatory progress, with topline data guided for Q4 2026 and H1 2027. Financially, the company highlighted ~$2.44 billion in cash and a completed $632.5M offering. Against this backdrop, today’s conference appearance fits as ongoing investor communication rather than a new fundamental catalyst.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN CARLOS, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that Company management will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026 at 2:15 p.m. ET / 11:15 a.m. PT.
A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise.
Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella. For more information, visit www.vaxcyte.com.
Contact:
Jeff Macdonald, Executive Director, Investor Relations
Vaxcyte, Inc.
917-371-0940
investors@vaxcyte.com
